STENOCARE announced on December 14th that the company has entered into a new partnership agreement w...
Gasporox has secured a SEK9.1m order for its VialArch product from MaxCann, with deliveries schedule...
Gabather tar ett viktigt steg framåt i utvecklingen av GT-002, en potentiell behandling för Frontall...
The market sentiment is picking up, and Calliditas is interesting ahead of the critical PDUFA date (...
Den nordamerikanska marknaden är den stora potentialen och risken I närtid ser vi extra god tillväxt...
Redeye endorses the news that Curasight has appointed a CRO, ABX-CRO, to conduct the upcoming phase ...
After the clarifications regarding NPCI’s UPI Lite X, RBI has now officially approved Crunchfish Dig...
Redeye comments on Enviro’s decision to appoint Fredrik Emilson as the new CEO.
Carbiotix AB (”Carbiotix” eller Bolaget”) har under Q4-23 erhållit Bolagets första marknadsgodkännan...
IRLAB has been granted a new patent for its Phase IIb asset, pirepemat, extending the predicted pate...
SBB presenterade i september en ny koncernstruktur som består av tre affärsenheter: Bostäder, Samhäl...
Redeye comments on Circio’s partner IOVaxis Therapeutics submission of an application to start a cli...
Redeye endorses the news that the company’s disease awareness activities have resulted in an additio...
Redeye comments on Vertex's bid to buy Pagero for SEK36 per share, valuing the company at about SEK5...
New financial targets Promising earnings outlook unchanged Limited earnings revisions expected, down...
Redeye has a positive first impression of Neonode's press release of today, where the company announ...
Redeye comments on Mentice buying all substantial assets of Biomodex, a Paris-based competitor in en...
Qbrick genomför nu en företrädesemission mellan 7-21 december om 7,5 MSEK, där teckningsåtagandet up...
Redeye is glad to see that OXE Marine managed to raise ~SEK30m in a directed share issue.
Gabather, ett forskningsbolag specialiserade inom innovativa neurologiska terapier, inleder ett sama...
